Big Pharma is gambling on specialized R&D. Will it pay off?

Big Pharma is gambling on specialized R&D. Will it pay off? is a pharma and life sciences industry update from PharmaVoice. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.

Kelly Bilodeau · 2026-05-20

Large pharma companies are taking bigger swings on fewer targets, which can be a risky strategy.

Source: PharmaVoice